Immuneering (IMRX) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Q32 Bio (QTTB) has outperformed Immuneering (IMRX) over the past year, gaining 217.1% versus a loss of 36.8%. Over five years, IMRX leads with a -84.5% price change compared with -92.8% for QTTB. Immuneering is the larger company by market cap ($240.7 million vs $239.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | QTTB |
|---|---|---|
| Share price | $3.72 | $8.04 |
| Market cap | $240.67M | $239.35M |
| 1-day change | -3.63% | +0.63% |
| YTD return | -41.34% | +140.66% |
| 1-year return | -36.82% | +217.06% |
| 5-year return | -84.47% | -92.84% |
| P/E ratio (TTM) | — | 2.55 |
| EPS (TTM) | $-0.93 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $23.57 |
| 52-week low | $3.60 | $1.91 |
| Distance from 52-week high | -56.13% | -65.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +361.56% | +392.54% |
| Average volume | 694.54K | 1.37M |
| Shares outstanding | 64.70M | 29.77M |
| Employees | 57 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed IMRX by 253.9 percentage points over the past year.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
IMRX vs QTTB FAQ
Which is bigger, Immuneering or Q32 Bio?
Immuneering (IMRX) is larger, with a market capitalization of $240.67M compared with $239.35M for Q32 Bio (QTTB).
Which stock has performed better over the past year, IMRX or QTTB?
QTTB returned +217.06% over the past 12 months, compared with -36.82% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.